Fig. 4
From: Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner
Tretinoin does not increase the efficacy of cyclophosphamide in alternative cell lines (A–E). Tumor bearing mice were treated with tretinoin 3 days before CY, for a total of nine doses at 10 mg/kg. CY was dosed at 200 mg/kg. Survival of mice inoculated with (A) CT26 colon carcinoma (n = 10, n = 5 for tretinoin group), (B) WEHI164 sarcoma (n = 5), (C) 4T1 breast cancer (n = 5), (D) AE17 murine mesothelioma (n = 5) or € Lewis lung carcinoma (n = 5, n = 10 for PBS). Significance was determined using the Mantel-Cox log-rank test. “ns” = not significant